{"id":6774,"date":"2024-09-16T10:01:06","date_gmt":"2024-09-16T14:01:06","guid":{"rendered":"https:\/\/bridgebio.local\/?page_id=6774"},"modified":"2024-09-30T07:44:00","modified_gmt":"2024-09-30T11:44:00","slug":"lgmd2i-r9","status":"publish","type":"page","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/","title":{"rendered":"what is LGMD2I\/R9?"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":37,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/page-affiliate.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6774","page","type-page","status-publish","hentry"],"acf":{"affiliate_color":{"color":"#479343","affiliate_body_class":"affiliate-LGMD limb-girdle"},"enable_exit_site_modal":true,"affiliate_hero":{"hero_header_size":"Big","background_image":{"ID":6775,"id":6775,"title":"affiliate-bg-green","filename":"affiliate-bg-green.jpg","filesize":247746,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green.jpg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/affiliate-bg-green\/","alt":"","author":"37","description":"","caption":"","name":"affiliate-bg-green","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:07:59","modified":"2024-09-16 14:07:59","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":2520,"height":1017,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-300x121.jpg","medium-width":300,"medium-height":121,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-768x310.jpg","medium_large-width":768,"medium_large-height":310,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-1024x413.jpg","large-width":1024,"large-height":413,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-1536x620.jpg","1536x1536-width":1536,"1536x1536-height":620,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affiliate-bg-green-2048x827.jpg","2048x2048-width":2048,"2048x2048-height":827}},"title":"what is limb-girdle muscular dystrophy type 2I\/R9?","content":"<p>Limb\u2011girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin\u2011related protein (<em>FKRP <\/em>) gene. People living with LGMD2I\/R9 experience progressive muscle degeneration and damage, and eventual loss of functional independence. BridgeBio, in partnership with the affiliate ML Bio Solutions, is committed to addressing the unmet needs of those affected by LGMD2I\/R9 through the development of a novel oral therapy.<\/p>\n","content_logo":{"ID":6783,"id":6783,"title":"MLBioSolutions_Inline_KO_White","filename":"MLBioSolutions_Inline_KO_White.svg","filesize":24739,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/mlbiosolutions_inline_ko_white\/","alt":"MLBio Solutions logo","author":"37","description":"","caption":"","name":"mlbiosolutions_inline_ko_white","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:21","modified":"2024-09-16 15:12:17","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/MLBioSolutions_Inline_KO_White.svg","2048x2048-width":1,"2048x2048-height":1}},"content_logo_link":"","button":{"title":"OUR RESEARCH","url":"\/lgmd2i-r9\/bbp-418\/","target":""},"image":{"ID":6791,"id":6791,"title":"what-is-hero","filename":"what-is-hero.webp","filesize":170964,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero.webp","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/what-is-hero\/","alt":"mother and daughter smiling and hugging, both connected to the LGMD2I\/R9 community","author":"37","description":"","caption":"","name":"what-is-hero","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:28","modified":"2024-09-16 15:10:59","menu_order":0,"mime_type":"image\/webp","type":"image","subtype":"webp","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":1340,"height":1468,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-150x150.webp","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-274x300.webp","medium-width":274,"medium-height":300,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-768x841.webp","medium_large-width":768,"medium_large-height":841,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-935x1024.webp","large-width":935,"large-height":1024,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero.webp","1536x1536-width":1340,"1536x1536-height":1468,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero.webp","2048x2048-width":1340,"2048x2048-height":1468}},"mobile_image":{"ID":6790,"id":6790,"title":"what-is-hero-mobile","filename":"what-is-hero-mobile.webp","filesize":91740,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile.webp","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/what-is-hero-mobile\/","alt":"mother and daughter smiling and hugging, both connected to the LGMD2I\/R9 community","author":"37","description":"","caption":"","name":"what-is-hero-mobile","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:27","modified":"2024-09-16 15:11:02","menu_order":0,"mime_type":"image\/webp","type":"image","subtype":"webp","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":1212,"height":1144,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile-150x150.webp","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile-300x283.webp","medium-width":300,"medium-height":283,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile-768x725.webp","medium_large-width":768,"medium_large-height":725,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile-1024x967.webp","large-width":1024,"large-height":967,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile.webp","1536x1536-width":1212,"1536x1536-height":1144,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/what-is-hero-mobile.webp","2048x2048-width":1212,"2048x2048-height":1144}}},"affiliate_blocks":[{"block_type":"image-text","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"right","image_size":"smaller","alternate_mobile_image":true,"image":{"ID":6796,"id":6796,"title":"affected-muscles-graphic-green","filename":"affected-muscles-graphic-green.svg","filesize":116966,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/affected-muscles-graphic-green\/","alt":"diagram showing muscles affected in LGMD2I\/R9, highlighting the heart, arms, diaphragm, intercostal muscles, and legs in green on a human silhouette","author":"37","description":"","caption":"","name":"affected-muscles-graphic-green","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:39","modified":"2024-09-16 15:10:13","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/affected-muscles-graphic-green.svg","2048x2048-width":1,"2048x2048-height":1}},"text":"<h2>LGMD2I\/R9<\/h2>\n<p>LGMD2I\/R9 is a rare, recessive genetic disorder caused by variants in the <em>FKRP<\/em> gene. This gene encodes FKRP, an enzyme involved in a chemical process called glycosylation, during which sugar molecules are attached to proteins. This chain of sugars, known as a glycan chain, allows a critical stabilizer of the muscle cell membrane, alpha\u2011dystroglycan, to function correctly. In people with LGMD2I\/R9, FKRP does not function at full capacity, leading to instability and injury of muscle cells. Physical symptoms of LGMD2I\/R9 typically include loss of muscle mass and muscle wasting, leading to muscle weakness in the legs, arms, and trunk. At later stages, respiratory and cardiac muscles may also grow weak, which can cause respiratory and cardiac complications. Genetic testing is the only way to confirm a diagnosis of LGMD2I\/R9.<\/p>\n","text_alternate":"<h3>glycosylated alpha\u2011dystroglycan<\/h3>\n<p>The major substrate of FKRP is alpha\u2011dystroglycan (\u03b1DG), which plays a critical role in stabilizing muscle cells. \u03b1DG is an essential component of the \u201cshock absorption\u201d system that exists to provide muscle cells with structural integrity. This system buffers muscle contractions and prevents scar tissue from forming during normal muscle use, such as during the beating of a heart, the expansion and contraction of the chest while breathing, and the movement of arm and leg muscles while walking.<\/p>\n","link":"","":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"image-row","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":[{"image_header":"Healthy muscle tissue","image":{"ID":6780,"id":6780,"title":"healthy-muscle-tissue-graphic","filename":"healthy-muscle-tissue-graphic.svg","filesize":124994,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/healthy-muscle-tissue-graphic\/","alt":"Diagram of healthy muscle tissue showing the interaction between the extracellular matrix and muscle cell membrane. The image highlights the glycan chain and the role of ISPD and FKRP enzymes in forming a stable connection between laminin in the extracellular matrix and the \u03b1DG protein in the muscle cell membrane. Below, a sequence illustrates how muscle lengthening contraction can lead to a small membrane tear, followed by the initiation of membrane repair, restoring the muscle structure.","author":"37","description":"","caption":"","name":"healthy-muscle-tissue-graphic","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:19","modified":"2024-09-16 15:12:41","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/healthy-muscle-tissue-graphic.svg","2048x2048-width":1,"2048x2048-height":1}},"mobile_image":false},{"image_header":"LGMD2I\/R9 muscle tissue","image":{"ID":6785,"id":6785,"title":"muscle-tissue-graphic-right-1","filename":"muscle-tissue-graphic-right-1.svg","filesize":112428,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","link":"https:\/\/bridgebio.com\/lgmd2i-r9\/muscle-tissue-graphic-right-1\/","alt":"Diagram of muscle tissue affected by LGMD2I\/R9 showing the disrupted interaction between the extracellular matrix and muscle cell membrane due to a mutant FKRP enzyme. The image indicates the incomplete glycan chain, leading to an unstable connection between laminin and the \u03b1DG protein. Below, a sequence shows how muscle lengthening contraction results in a small membrane tear, which, due to the inability to stabilize and repair the membrane, leads to progressive muscle damage.","author":"37","description":"","caption":"","name":"muscle-tissue-graphic-right-1","status":"inherit","uploaded_to":6774,"date":"2024-09-16 14:08:22","modified":"2024-09-16 15:11:39","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/bridgebio.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/bridgebio.com\/wp-content\/uploads\/2024\/09\/muscle-tissue-graphic-right-1.svg","2048x2048-width":1,"2048x2048-height":1}},"mobile_image":false}],"image_footnotes":"<p><strong>\u03b1DG<\/strong>, alpha\u2011dystroglycan; <strong>CDP<\/strong>, cytidine diphosphate; <strong>CTP<\/strong>, cytidine triphosphate; <strong>FKRP<\/strong>, fukutin\u2011related protein; <strong>ISPD<\/strong>, isoprenoid synthase domain\u2011containing protein; <strong>LGMD2I\/R9<\/strong>, limb\u2011girdle muscular dystrophy type 2I\/R9; <strong>P<\/strong>, phosphate; <strong>R<\/strong>, ribitol.<\/p>\n"},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"text-block","text_block":{"content":"<p style=\"text-align: left;\">To function, \u03b1DG requires glycosylation by FKRP, which adds sugars to \u03b1DG in an assembly line\u2011like fashion. In people with LGMD2I\/R9, FKRP does not function at full capacity, and \u03b1DG does not become fully glycosylated. As a result, the shock absorber function is lost, causing muscles to become damaged with use and eventually form scar\u2011like, fibrotic tissue. As the proportion of fibrotic tissue within the muscle increases, there is a decline in muscle strength and function. Loss of muscle strength eventually causes people affected by LGMD2I\/R9 to lose the ability to perform routine daily activities, such as walking or standing up, without assistance.<\/p>\n","external_link":{"title":"Read about our approach","url":"\/lgmd2i-r9\/bbp-418\/","target":""},"center_link":true},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"articles","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"","image_size":"","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":null,"":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":[{"link":{"title":"BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I\/R9 (LGMD2I\/R9)","url":"http:\/\/bridgebio.com\/news\/bridgebio-completes-enrollment-of-fortify-phase-3-registrational-study-of-bbp-418-in-limb-girdle-muscular-dystrophy-type-2i-r9-lgmd2i-r9\/","target":""},"date":"09.30.2024"},{"link":{"title":"BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I\/R9 (LGMD2I\/R9)","url":"http:\/\/bridgebio.com\/news\/bridgebio-pharma-surpasses-interim-analysis-enrollment-target-and-receives-u-s-fda-rare-pediatric-disease-designation-for-bbp-418-a-potential-treatment-for-limb-girdle-muscular-dystrophy-type-2i-r9\/","target":""},"date":"07.18.2024"}],"manual_button_content":true,"button_link":{"title":"SEE MORE","url":"\/news\/","target":""},"display_single_column":true},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":false,"manual_buttone_content":false,"button_link":null,"display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null},{"block_type":"publications","text_block":{"content":"","external_link":null,"center_link":false},"callout_text":{"callout_content":"","text_color":"null"},"image_text_block":{"image_position":"left","image_size":"big","alternate_mobile_image":false,"image":false,"text":"","text_alternate":"","link":"","":""},"image_row":{"images":false,"image_footnotes":""},"patients_block":{"title":"patient stories","patients":false},"facts_block":{"title":"","facts":false},"resources_block":{"title":"","main_content":"","resources":false},"external_resources":{"title":"related news","use_parent_resources":false,"articles":false,"manual_button_content":false,"button_link":null,"display_single_column":false},"presentations_block":{"title":"presentations and publications","use_parent_resources":false,"publications":[{"link":{"title":"MENA 2024 \u2013 Oral Presentation","url":"https:\/\/investor.bridgebiodev.wpengine.com\/static-files\/b55794a2-3b71-4cf8-b383-d9ca735caa55","target":"_blank"},"date":"05.16.2024"},{"link":{"title":"MDA 2024 \u2013 Development of PROMIS Tool","url":"https:\/\/investor.bridgebiodev.wpengine.com\/static-files\/912abc07-622e-4771-b448-332609a2887d","target":"_blank"},"date":""},{"link":{"title":"Journal of Muscle Research and Cell Motility, Validation of a Novel Western Blot Assay to Monitor Patterns and Levels of Alpha Dystroglycan in Skeletal Muscle of Patients with Limb-girdle Muscular Dystrophies","url":"\/wp-content\/uploads\/2024\/07\/Rajasingham-2024.pdf","target":"_blank"},"date":"04.18.2024"},{"link":{"title":"PLOS One, Ribitol Dose-dependently Enhances Matriglycan Expression and Improves Muscle Function with Prolonged Life Span in Limb-girdle Muscular Dystrophy 2I\/R9 Mouse Model","url":"\/wp-content\/uploads\/2024\/07\/Wu-2022_ribitol-6-month-p448L-mouse.pdf","target":"_blank"},"date":"12.01.2022"},{"link":{"title":"Nature Communications, Ribitol Restores Functionally Glycosylated Alpha-dystroglycan and Improves Muscle Function in Dystrophic FKRP-mutant Mice","url":"\/wp-content\/uploads\/2024\/07\/Cataldi-2018.pdf","target":"_blank"},"date":"08.27.2018"}],"manual_buttone_content":false,"button_link":"","display_single_column":false},"posts_section":{"title":"featured posts","featured_posts":null},"references":"","cta_button":null}],"footer_reference_number":"MAT-US\u2014401"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?<\/title>\n<meta name=\"description\" content=\"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/lgmd2i-r9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?\" \/>\n<meta property=\"og:description\" content=\"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/lgmd2i-r9\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-30T11:44:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/\",\"url\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/\",\"name\":\"LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2024-09-16T14:01:06+00:00\",\"dateModified\":\"2024-09-30T11:44:00+00:00\",\"description\":\"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/lgmd2i-r9\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/lgmd2i-r9\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"what is LGMD2I\/R9?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?","description":"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/lgmd2i-r9\/","og_locale":"en_US","og_type":"article","og_title":"LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?","og_description":"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.","og_url":"https:\/\/bridgebio.com\/lgmd2i-r9\/","og_site_name":"BridgeBio","article_modified_time":"2024-09-30T11:44:00+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BridgeBioPharma","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/","url":"https:\/\/bridgebio.com\/lgmd2i-r9\/","name":"LGMD2I\/R9 | What Is Limb Girdle Muscular Dystrophy 2I\/R9?","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2024-09-16T14:01:06+00:00","dateModified":"2024-09-30T11:44:00+00:00","description":"Limb-girdle muscular dystrophy type 2I\/R9 (LGMD2I\/R9) is a rare genetic disorder caused by variants in the fukutin-related protein gene. Learn more.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/lgmd2i-r9\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/lgmd2i-r9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"what is LGMD2I\/R9?"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6774"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=6774"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/pages\/6774\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=6774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}